[{"from": "human", "value": "Describe this molecule. [C][C][Branch2][Branch1][=Branch2][C][=Branch1][C][=O][N][Branch2][Ring1][O][C][=Branch1][C][=S][N][Ring1][#Branch1][C][=C][C][=Branch1][=C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=Branch1][C][=O][N][C][F][C][=C][C][=Branch1][#Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][#N][C][Branch1][C][F][Branch1][C][F][F][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance."}]